CD123 CAR-T cell therapy
/ Chongqing Precision Biotech
- LARVOL DELTA
Home
Next
Prev
1 to 4
Of
4
Go to page
1
April 18, 2023
Safety and Efficacy of CD123-Targeted CAR-T Therapy for Relapsed/Refractory Acute Myeloid Leukemia
(clinicaltrials.gov)
- P1/2 | N=40 | Recruiting | Sponsor: Chongqing Precision Biotech Co., Ltd | Trial completion date: Jul 2023 ➔ Jul 2024 | Trial primary completion date: Dec 2022 ➔ Dec 2023
Trial completion date • Trial primary completion date • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology • CD123
April 18, 2023
CD123-Targeted CAR-T Cell Therapy for Relapsed/Refractory Acute Myeloid Leukemia
(clinicaltrials.gov)
- P1/2 | N=45 | Recruiting | Sponsor: Chongqing Precision Biotech Co., Ltd | Trial completion date: Jul 2022 ➔ Jul 2024 | Trial primary completion date: Dec 2021 ➔ Dec 2023
CAR T-Cell Therapy • Trial completion date • Trial primary completion date • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology • CD123
February 17, 2020
Safety and Efficacy of CD123-Targeted CAR-T Therapy for Relapsed/Refractory Acute Myeloid Leukemia
(clinicaltrials.gov)
- P1/2; N=40; Recruiting; Sponsor: Chongqing Precision Biotech Co., Ltd
Clinical • New P1/2 trial • CD123
February 12, 2020
CD123 CAR-T Cell Therapy for Relapsed and Refractory Acute Myeloid Leukemia
(clinicaltrials.gov)
- P1/2; N=45; Recruiting; Sponsor: Chongqing Precision Biotech Co., Ltd
CAR T-Cell Therapy • New P1/2 trial
1 to 4
Of
4
Go to page
1